Literature DB >> 32235945

Virological assessment of hospitalized patients with COVID-2019.

Roman Wölfel1, Victor M Corman2, Wolfgang Guggemos3, Michael Seilmaier3, Sabine Zange1, Marcel A Müller2, Daniela Niemeyer2, Terry C Jones2,4, Patrick Vollmar1, Camilla Rothe5, Michael Hoelscher5, Tobias Bleicker2, Sebastian Brünink2, Julia Schneider2, Rosina Ehmann1, Katrin Zwirglmaier1, Christian Drosten6, Clemens Wendtner7.   

Abstract

Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 20191,2. Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses3. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung2,4; the same receptor tropism is thought to have determined the pathogenicity-but also aided in the control-of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11 × 108 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples-in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32235945     DOI: 10.1038/s41586-020-2196-x

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  3 in total

1.  Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.

Authors:  V M Corman; M A Müller; U Costabel; J Timm; T Binger; B Meyer; P Kreher; E Lattwein; M Eschbach-Bludau; A Nitsche; T Bleicker; O Landt; B Schweiger; J F Drexler; A D Osterhaus; B L Haagmans; U Dittmer; F Bonin; T Wolff; C Drosten
Journal:  Euro Surveill       Date:  2012-12-06

2.  Characterization of two new electrophoretic variants of human triosephosphate isomerase: stability, kinetic, and immunological properties.

Authors:  J Asakawa; H W Mohrenweiser
Journal:  Biochem Genet       Date:  1982-02       Impact factor: 1.890

3.  Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection.

Authors:  Victor M Corman; Ali M Albarrak; Ali Senosi Omrani; Mohammed M Albarrak; Mohamed Elamin Farah; Malak Almasri; Doreen Muth; Andrea Sieberg; Benjamin Meyer; Abdullah M Assiri; Tabea Binger; Katja Steinhagen; Erik Lattwein; Jaffar Al-Tawfiq; Marcel A Müller; Christian Drosten; Ziad A Memish
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

  3 in total
  2000 in total

1.  Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.

Authors:  Xufang Deng; Alexandra C Buckley; Angela Pillatzki; Kelly M Lager; Kay S Faaberg; Susan C Baker
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 2. 

Authors:  Paul Van Caeseele; Dana Bailey; Sarah E Forgie; Tanis C Dingle; Mel Krajden
Journal:  CMAJ       Date:  2020-12-07       Impact factor: 8.262

3.  SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP.

Authors:  José Zúñiga; Néstor Toapanta; Natalia Ramos; Sonia Caparros; Juan León-Roman; María Azancot; Clara Garcia-Carro; Eugenia Espinel; Daniel Seron; María José Soler
Journal:  Nefrologia (Engl Ed)       Date:  2021-01-28

4.  Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19.

Authors:  Ji Hoon Ahn; JungMo Kim; Seon Pyo Hong; Sung Yong Choi; Myung Jin Yang; Young Seok Ju; Young Tae Kim; Ho Min Kim; M D Tazikur Rahman; Man Ki Chung; Sang Duk Hong; Hosung Bae; Chang-Seop Lee; Gou Young Koh
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

5.  Management of IBD Patients During the COVID-19 Pandemic.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-11

Review 6.  Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical UIse.

Authors:  Daniel Shyu; James Dorroh; Caleb Holtmeyer; Detlef Ritter; Anandhi Upendran; Raghuraman Kannan; Dima Dandachi; Christian Rojas-Moreno; Stevan P Whitt; Hariharan Regunath
Journal:  Mo Med       Date:  2020 May-Jun

7.  SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease.

Authors:  Thomas J Gniadek; Joshua M Thiede; William E Matchett; Abigail R Gress; Kathryn A Pape; Jessica K Fiege; Marc K Jenkins; Vineet D Menachery; Ryan A Langlois; Tyler D Bold
Journal:  Transfusion       Date:  2020-10-02       Impact factor: 3.157

8.  Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.

Authors:  Carina Conzelmann; Janis A Müller; Lukas Perkhofer; Konstantin Mj Sparrer; Alexander N Zelikin; Jan Münch; Alexander Kleger
Journal:  Clin Med (Lond)       Date:  2020-08-30       Impact factor: 2.659

9.  What We Need to Consider During and After the SARS-CoV-2 Pandemic.

Authors:  Willy A Valdivia-Granda; Jürgen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2020-05-29       Impact factor: 2.133

10.  SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.

Authors:  Rafal Bartoszewski; Michal Dabrowski; Bogdan Jakiela; Sadis Matalon; Kevin S Harrod; Marek Sanak; James F Collawn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.